Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 500 versus TRIMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 500 versus TRIMOX.
AUGMENTIN '500' vs TRIMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin is a semisynthetic aminopenicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting cell wall integrity, leading to bacteriolysis. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates a broad range of beta-lactamases, preventing degradation of amoxicillin and extending its spectrum to include beta-lactamase-producing bacteria.
Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis and death.
1 tablet (amoxicillin 500 mg / clavulanate 125 mg) orally every 8 hours or 1 tablet (amoxicillin 875 mg / clavulanate 125 mg) orally every 12 hours for mild to moderate infections. For severe infections, use 875 mg/125 mg every 12 hours.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours depending on infection severity.
None Documented
None Documented
Amoxicillin: 1-1.3 hours; clavulanate: 1 hour. In renal impairment (CrCl <30 mL/min): amoxicillin 7-20 hours, clavulanate 4-6 hours. Extends dosing interval.
Terminal elimination half-life: 1-1.5 hours (normal renal function); in renal impairment (CrCl <10 mL/min), extends to 6-20 hours, requiring dose adjustment.
Renal excretion 50-70% (amoxicillin) and 40-60% (clavulanate) as unchanged drug; tubular secretion and glomerular filtration. Fecal elimination <10%.
Renal: 50-85% unchanged via glomerular filtration and tubular secretion; biliary/fecal: minimal, <5%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic